Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.
After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.
Meitheal has announced a licensing agreement with parent company Hong Kong King-Friend to add another three biosimilars to its pipeline for the US market.
A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva’s Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.
Zentiva has responded to recent rumors that owner Advent International may be looking to sell the firm in a deal worth as much as €5bn.
After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.
Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.
Attended by several government delegates, the opening of the multi-million dollar antibiotic plant highlighted the Indian government’s ongoing policy to bolster domestic pharmaceutical manufacturing.
Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.
Sandoz has raised its full-year guidance on the back of third-quarter results that saw the firm enjoy growth of more than a tenth, with biosimilars sales up by a whopping 37%.
Only days after its initial announcement, Hypera Pharma has refused EMS’ proposed merger on grounds of undervaluation and different strategic priorities.
Generics Bulletin previews the most noteworthy and anticipated events for November 2024.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.
In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.
While the firm’s mind and money continues to gear towards branded and novel drugs, India’s Sun Pharma still maintains a mammoth global generics business, including in the US where Sun saw a healthy leap in sales during its financial second quarter.
After a “remarkable performance” in Q2, Samsung Bioepis enjoyed a calm, but still profitable, third quarter.
Celltrion gave updates on several business aspects and reassured its shareholders that the delayed insurance listing for Zymfentra will not affect its set annual sales goal.
Xbrane Biopharma is on the clock to bring in a licensing partner for one of its two biosimilar candidates in order to fulfil its short-term working capital requirements. The Swedish firm has revealed that a deal for one appears close, as it also reached an agreement for more time to put pen to paper.
Backed by AI and former FDA official Janet Woodcock, Every Cure is set to identify approved drugs for patients who don’t have treatment options around the world.
Zentiva has launched a bid to take control of German “single pill company” Apontis Pharma, with a €10-per-share offer that values the enterprise at €85m. If successful, Zentiva plans to establish the firm as a standalone branded division.